ReviewGlomerular diseases
Quantitative Proteomics: Recent Advances in Glomerular Disease and Nephrotic Syndrome.
Review in Glomerular diseases. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Chronic kidney disease (CKD) affects nearly 10% (∼850 million people) of the global population and stands among leading causes of morbidity, mortality, and healthcare cost. Current clinical biomarkers including serum creatinine, estimated glomerular filtration rate (eGFR), and proteinuria, are all lagging indicators of nephron damage only after glomerular and podocyte injury and are often coincident with tubule damage and fibrosis and indicative of advanced CKD. Summary: This review summarizes recent progress in proteomics applications in CKD and glomerular diseases, emphasizing biomarker discovery, mechanistic understanding, and translational potential. Finally, we discuss current challenges, future directions, and goals integrating proteomics into clinical nephrology and advancing personalized care. Key Messages: Quantitative proteomics has emerged as a powerful molecular methodology to identify novel biomarkers toward delineating disease mechanism across plasma, urine, and renal tissue. Advances in quantitative mass spectrometry, single-cell, and spatial proteomics now enable high-resolution characterization of glomerular and tubular pathobiology, offering new opportunities for early detection, risk stratification, and precision therapeutics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.